Trial · NCT04649151
Adverse events612
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 612
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Part 1A: mRNA-1273 100 μg | 8 | 2,486 | 9 |
| other | Abdominal pain | Gastrointestinal disorders | Part 1A: Placebo | 3 | 1,240 | 3 |
| other | Abdominal pain | Gastrointestinal disorders | Part 1B: mRNA-1273 100 µg | 0 | 96 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Part 1C-1: mRNA-1273 50 µg BD | 6 | 1,408 | 6 |
| other | Abdominal pain | Gastrointestinal disorders | Part 1C-2: mRNA-1273 50 μg BD | 0 | 155 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Part 2: mRNA-1273 50 μg | 0 | 52 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Part 2: mRNA-1273 50 ug BD | 1 | 19 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Part 3: mRNA1273.222 50 µg 1 Dose | 1 | 388 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Part 3: mRNA-1273.222 50 ug Second Dose | 1 | 335 | 1 |
| other | Injection site lymphadenopathy | General disorders | Part 1A: mRNA-1273 100 μg | 137 | 2,486 | 146 |
| other | Injection site lymphadenopathy | General disorders | Part 1A: Placebo | 6 | 1,240 | 6 |
| other | Injection site lymphadenopathy | General disorders | Part 1B: mRNA-1273 100 µg | 0 | 96 | 0 |
| other | Injection site lymphadenopathy | General disorders | Part 1C-1: mRNA-1273 50 µg BD | 5 | 1,408 | 5 |
| other | Injection site lymphadenopathy | General disorders | Part 1C-2: mRNA-1273 50 μg BD | 0 | 155 | 0 |
| other | Injection site lymphadenopathy | General disorders | Part 2: mRNA-1273 50 μg | 1 | 52 | 1 |
| other | Injection site lymphadenopathy | General disorders | Part 2: mRNA-1273 50 ug BD | 0 | 19 | 0 |
| other | Injection site lymphadenopathy | General disorders | Part 3: mRNA1273.222 50 µg 1 Dose | 0 | 388 | 0 |
| other | Injection site lymphadenopathy | General disorders | Part 3: mRNA-1273.222 50 ug Second Dose | 0 | 335 | 0 |
| other | Respiratory tract infection | Infections and infestations | Part 1A: mRNA-1273 100 μg | 11 | 2,486 | 12 |
| other | Respiratory tract infection | Infections and infestations | Part 1A: Placebo | 4 | 1,240 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04649151/events